États-Unis · Bourse & Finance · Yahoo Finance

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Publié par Yahoo Finance · États-Unis il y a 8 h

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

À lire aussi

Business Insider

I moved back to my boring hometown. As a parent, boring looks pretty good.

CFTC Draws the Line Between Prediction Markets and Gambling in New Rules

Petra Power looks to modernize energy for data centers and defense vehicles

Flight disruptions growing after missile attack on Saudi airport

‘Fantasy economics’: Baby boomer vs. Gen Z tensions hit France as pension costs drive debt crisis and education cuts that fuel student protests

Kasai, Klarity and 8 other baby names surging in America